AKTIS ONCOLOGY INC (AKTS) Stock Price, Forecast & Analysis

NASDAQ:AKTS • US01021M1045

18.22 USD
+0.59 (+3.35%)
Last: Feb 19, 2026, 02:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AKTS Key Statistics, Chart & Performance

Key Statistics
Market Cap922.84M
Revenue(TTM)1.49M
Net Income(TTM)-43.98M
Shares50.65M
Float44.09M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.87
PEN/A
Fwd PEN/A
Earnings (Next)02-11
IPO2026-01-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
AKTS short term performance overview.The bars show the price performance of AKTS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

AKTS long term performance overview.The bars show the price performance of AKTS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of AKTS is 18.22 USD. In the past month the price decreased by -6.07%.

AKTIS ONCOLOGY INC / AKTS Daily stock chart

AKTS Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to AKTS.


Chartmill TA Rating
Chartmill Setup Rating
AKTS Full Technical Analysis Report

AKTS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to AKTS. While AKTS has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AKTS Full Fundamental Analysis Report

AKTS Financial Highlights

Over the last trailing twelve months AKTS reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS decreased by -53.55% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.76%
ROE -21.88%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-52.21%
Sales Q2Q%-38.39%
EPS 1Y (TTM)-53.55%
Revenue 1Y (TTM)N/A
AKTS financials

AKTS Forecast & Estimates

For the next year, analysts expect an EPS growth of 42.58% and a revenue growth 29.7% for AKTS


Analysts
Analysts45.71
Price TargetN/A
EPS Next Y42.58%
Revenue Next Year29.7%
AKTS Analyst EstimatesAKTS Analyst Ratings

AKTS Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %0.44%
Short Ratio0.7
AKTS Ownership

AKTS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.44404.235B
AMGN AMGEN INC16.66204.477B
GILD GILEAD SCIENCES INC16.99189.501B
VRTX VERTEX PHARMACEUTICALS INC22.97119.327B
REGN REGENERON PHARMACEUTICALS16.7883.747B
ALNY ALNYLAM PHARMACEUTICALS INC50.343.95B
INSM INSMED INC N/A32.227B
NTRA NATERA INC N/A29.989B
BIIB BIOGEN INC12.6228.491B
UTHR UNITED THERAPEUTICS CORP16.320.499B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About AKTS

Company Profile

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company is headquartered in Boston, Massachusetts. The company went IPO on 2026-01-09. The firm focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. The company also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. The company transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.

Company Info

AKTIS ONCOLOGY INC

17 Drydock Avenue, Suite #17-401

Boston MASSACHUSETTS 28078 US

CEO: Jeffrey B. Shealy

Employees: 117

AKTS Company Website

Phone: 13026587581

AKTIS ONCOLOGY INC / AKTS FAQ

What does AKTIS ONCOLOGY INC do?

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company is headquartered in Boston, Massachusetts. The company went IPO on 2026-01-09. The firm focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. The company also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. The company transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.


What is the current price of AKTS stock?

The current stock price of AKTS is 18.22 USD. The price increased by 3.35% in the last trading session.


Does AKTIS ONCOLOGY INC pay dividends?

AKTS does not pay a dividend.


How is the ChartMill rating for AKTIS ONCOLOGY INC?

AKTS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Where is AKTIS ONCOLOGY INC (AKTS) stock traded?

AKTS stock is listed on the Nasdaq exchange.


What is the employee count for AKTS stock?

AKTIS ONCOLOGY INC (AKTS) currently has 117 employees.